Publications 2024

Bischof K, Holth A, Bassarova A, Davidson B (2024)
Expression of PRAME in high-grade serous carcinoma is associated with higher residual disease volume and Occludin expression
Pathol Res Pract, 266, 155787 (in press)
DOI 10.1016/j.prp.2024.155787, PubMed 39709875

Davidson B, Doutel D, Holth A, Nymoen DA (2024)
Correction to: Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma
Virchows Arch, 484 (5), 875
DOI 10.1007/s00428-023-03567-w, PubMed 37261507

Davidson B, Holth A, Hummel C, Flatmark K, Torgunrud A (2024)
Different Frequency and Clinical Role for MTAP Loss in Pleural and Peritoneal Mesothelioma
Appl Immunohistochem Mol Morphol, 32 (6), 280-284
DOI 10.1097/PAI.0000000000001206, PubMed 38812360

Davidson B, Holth A, Lindemann K, Zahl Eriksson AG, Nilsen TA, Torgunrud A (2024)
Molecular characteristics of tubo-ovarian carcinosarcoma at different anatomic locations
Virchows Arch, 485 (6), 1053-1061
DOI 10.1007/s00428-024-03821-9, PubMed 38733380

Davidson B, Skeie-Jensen T, Holth A, Hausladen S (2024)
Stathmin is an Independent Prognostic Marker of Poor Outcome in Uterine Leiomyosarcoma
Int J Gynecol Pathol, 44 (1), 56-66
DOI 10.1097/PGP.0000000000001030, PubMed 38847524

Davidson B, Teien Lande K, Nebdal D, Nesbakken AJ, Holth A, Lindemann K, Zahl Eriksson AG, Sørlie T (2024)
Endometrial carcinomas with ambiguous histology often harbor TP53 mutations
Virchows Arch (in press)
DOI 10.1007/s00428-024-03912-7, PubMed 39235515

Publications 2023

Davidson B, Doutel D, Holth A, Nymoen DA (2023)
Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma
Virchows Arch, 482 (6), 975-982
DOI 10.1007/s00428-023-03541-6, PubMed 37067588

Davidson B, Skeie-Jensen T, Holth A, Lindemann K, Toralba Barrameda AM, Lie AK, Wang Y (2023)
Lymphovascular invasion and p16 expression are independent prognostic factors in stage I vulvar squamous cell carcinoma
Virchows Arch, 484 (6), 951-963
DOI 10.1007/s00428-023-03670-y, PubMed 37843640

Dos Santos MV, Holth A, Bischof K, Davidson B (2023)
Occludin is overexpressed in tubo-ovarian high-grade serous carcinoma compared to mesothelioma and is a marker of tumor progression and chemoresistance
Clin Exp Metastasis, 41 (1), 69-76
DOI 10.1007/s10585-023-10251-5, PubMed 38141113

Dos Santos MV, Holth A, Lindemann K, Staff AC, Davidson B (2023)
Clinical significance of L1CAM expression in metastatic tubo-ovarian high-grade serous carcinoma
Gynecol Oncol, 176, 76-81
DOI 10.1016/j.ygyno.2023.07.004, PubMed 37478615

Publications 2020

Davidson B, Bock AJ, Holth A, Nymoen DA (2020)
Expression of palladin is associated with disease progression in metastatic high-grade serous carcinoma
Cytopathology, 31 (6), 572-578
DOI 10.1111/cyt.12895, PubMed 32741023

Davidson B, Bock AJ, Holth A, Nymoen DA (2020)
The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma
Cytopathology, 32 (2), 161-168
DOI 10.1111/cyt.12921, PubMed 33025675

Davidson B, Holth A, Dong HP (2020)
Expression of the cancer stem cell marker SSEA1 is associated with poor survival in metastatic high-grade serous carcinoma
Virchows Arch, 477 (5), 677-685
DOI 10.1007/s00428-020-02850-4, PubMed 32472195

Davidson B, McFadden E, Holth A, Brunetti M, Flørenes VA (2020)
Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma
Virchows Arch, 477 (6), 857-864
DOI 10.1007/s00428-020-02842-4, PubMed 32533344

Panagopoulos I, Gorunova L, Johannsdottir IMR, Andersen K, Holth A, Beiske K, Heim S (2020)
Chromosome Translocation t(14;21)(q11;q22) Activates Both OLIG1 and OLIG2 in Pediatric T-cell Lymphoblastic Malignancies and May Signify Adverse Prognosis
Cancer Genomics Proteomics, 17 (1), 41-48
DOI 10.21873/cgp.20166, PubMed 31882550

Publications 2019

Dominguez-Valentin M, Nakken S, Tubeuf H, Vodak D, Ekstrøm PO, Nissen AM, Morak M, Holinski-Feder E, Holth A, Capella G, Davidson B, Evans DG, Martins A, Møller P, Hovig E (2019)
Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing
Sci Rep, 9 (1), 18555
DOI 10.1038/s41598-019-54517-z, PubMed 31811167

Panagopoulos I, Gorunova L, Lobmaier I, Lund-Iversen M, Andersen K, Holth A, Bjerkehagen B, Heim S (2019)
Fusion of the COL1A1 and FYN Genes in Epithelioid Osteoblastoma
Cancer Genomics Proteomics, 16 (5), 361-368
DOI 10.21873/cgp.20141, PubMed 31467230

Sherman-Samis M, Onallah H, Holth A, Reich R, Davidson B (2019)
SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma
Gynecol Oncol, 153 (3), 651-660
DOI 10.1016/j.ygyno.2019.03.099, PubMed 30904337

Publications 2018

Brunetti M, Holth A, Panagopoulos I, Staff AC, Micci F, Davidson B (2018)
Expression and clinical role of the dipeptidyl peptidases DPP8 and DPP9 in ovarian carcinoma
Virchows Arch, 474 (2), 177-185
DOI 10.1007/s00428-018-2487-x, PubMed 30467600

Davidson B, Bjørnerem M, Holth A, Hellesylt E, Hetland Falkenthal TE, Flørenes VA (2018)
Expression, activation and clinical relevance of CHK1 and CHK2 in metastatic high-grade serous carcinoma
Gynecol Oncol, 150 (1), 136-142
DOI 10.1016/j.ygyno.2018.05.007, PubMed 29804637

Davidson B, Holth A, Wang Z, Hellsylt E, Tropé CG, Hetland Falkenthal TE, Holm R (2018)
Expression of 14-3-3 sigma and eta proteins is unrelated to survival in metastatic high-grade serous carcinoma
APMIS, 126 (4), 309-313
DOI 10.1111/apm.12816, PubMed 29464778

Publications 2017

Davidson B, Hellesylt E, Holth A, Danielsen HE, Skeie-Jensen T, Katz B (2017)
Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma
Virchows Arch, 471 (3), 355-362
DOI 10.1007/s00428-017-2172-5, PubMed 28643014

Davidson B, Pinamonti M, Cuevas D, Holth A, Zeppa P, Hager T, Wohlschlaeger J, Tötsch M (2017)
The diagnostic role of PTEN and ARID1A in serous effusions
Virchows Arch, 472 (3), 425-432
DOI 10.1007/s00428-017-2273-1, PubMed 29170871

Gutgold N, Davidson B, Catane LJ, Holth A, Hellesylt E, Tropé CG, Dørum A, Reich R (2017)
TGFβ splicing and canonical pathway activation in high-grade serous carcinoma
Virchows Arch, 470 (6), 665-678
DOI 10.1007/s00428-017-2127-x, PubMed 28432432

Publications 2016

Nymoen DA, Slipicevic A, Holth A, Emilsen E, Hetland Falkenthal TE, Tropé CG, Reich R, Flørenes VA, Davidson B (2016)
MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma
Hum Pathol, 54, 74-81
DOI 10.1016/j.humpath.2016.03.010, PubMed 27063471

Smogeli E, Davidson B, Cvancarova M, Holth A, Katz B, Risberg B, Kristensen G, Lindemann K (2016)
L1CAM as a prognostic marker in stage I endometrial cancer: a validation study
BMC Cancer, 16, 596
DOI 10.1186/s12885-016-2631-4, PubMed 27488577

Publications 2015

Davidson B, Holth A, Hellesylt E, Hadar R, Katz B, Tropé CG, Reich R (2015)
HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival
Hum Pathol, 48, 95-101
DOI 10.1016/j.humpath.2015.09.027, PubMed 26640230

Nymoen DA, Hetland Falkenthal TE, Holth A, Ow GS, Ivshina AV, Tropé CG, Kuznetsov VA, Staff AC, Davidson B (2015)
Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma
Gynecol Oncol, 139 (1), 30-9
DOI 10.1016/j.ygyno.2015.07.107, PubMed 26232338

Nymoen DA, Holth A, Hetland Falkenthal TE, Tropé CG, Davidson B (2015)
CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma
Mol Cancer, 14, 44
DOI 10.1186/s12943-015-0317-1, PubMed 25889687

Publications 2014

Davidson B, Holth A, Hellesylt E, Tan TZ, Huang RY, Tropé C, Nesland JM, Thiery JP (2014)
The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions
Hum Pathol, 46 (1), 1-8
DOI 10.1016/j.humpath.2014.10.004, PubMed 25455994

Davidson B, Rosenfeld YB, Holth A, Hellesylt E, Tropé CG, Reich R, Yisraeli JK (2014)
VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival
Hum Pathol, 45 (7), 1520-8
DOI 10.1016/j.humpath.2014.03.005, PubMed 24814803

Slipicevic A, Holth A, Hellesylt E, Tropé CG, Davidson B, Flørenes VA (2014)
Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions
Gynecol Oncol, 135 (1), 118-24
DOI 10.1016/j.ygyno.2014.07.102, PubMed 25093290

Publications 2013

Davidson B, Abeler VM, Førsund M, Holth A, Yang Y, Kobayashi Y, Chen L, Kristensen GB, Shih IeM, Wang TL (2013)
Gene expression signatures of primary and metastatic uterine leiomyosarcoma
Hum Pathol, 45 (4), 691-700
DOI 10.1016/j.humpath.2013.11.003, PubMed 24485798

Stavnes HT, Holth A, Don T, Kærn J, Vaksman O, Reich R, Trope' CG, Davidson B (2013)
HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival
Gynecol Oncol, 129 (2), 358-63
DOI 10.1016/j.ygyno.2013.02.021, PubMed 23438671

Publications 2012

Davidson B, Abeler VM, Hellesylt E, Holth A, Shih IeM, Skeie-Jensen T, Chen L, Yang Y, Wang TL (2012)
Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma
Gynecol Oncol, 128 (2), 349-55
DOI 10.1016/j.ygyno.2012.11.021, PubMed 23178314

Davidson B, Holth A, Nguyen MT, Tropé CG, Wu C (2012)
Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases
Gynecol Oncol, 128 (2), 364-70
DOI 10.1016/j.ygyno.2012.10.015, PubMed 23099104

Hetland TE, Holth A, Kærn J, Flørenes VA, Tropé CG, Davidson B (2012)
HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases
Virchows Arch, 460 (5), 505-13
DOI 10.1007/s00428-012-1228-9, PubMed 22476403

Hetland TE, Nymoen DA, Holth A, Brusegard K, Flørenes VA, Kærn J, Tropé CG, Davidson B (2012)
Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance
Hum Pathol, 44 (5), 777-85
DOI 10.1016/j.humpath.2012.08.002, PubMed 23114921

Stavnes HT, Nymoen DA, Langerød A, Holth A, Børresen Dale AL, Davidson B (2012)
AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma
Virchows Arch, 462 (2), 163-73
DOI 10.1007/s00428-012-1347-3, PubMed 23242172

Publications 2011

Davidson B, Holth A, Moripen L, Trope' CG, Shih IeM (2011)
Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome
Hum Pathol, 42 (7), 991-7
DOI 10.1016/j.humpath.2010.10.013, PubMed 21315424

Davidson B, Stavnes HT, Holth A, Chen X, Yang Y, Shih IeM, Wang TL (2011)
Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions
J Cell Mol Med, 15 (3), 535-44
DOI 10.1111/j.1582-4934.2010.01023.x, PubMed 20132413

Publications 2010

Bunkholt Elstrand M, Dong HP, Ødegaard E, Holth A, Elloul S, Reich R, Tropé CG, Davidson B (2010)
Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma
Hum Pathol, 41 (6), 794-804
DOI 10.1016/j.humpath.2009.09.017, PubMed 20153512

Publications 2009

Dong HP, Holth A, Kleinberg L, Ruud MG, Elstrand MB, Tropé CG, Davidson B, Risberg B (2009)
Evaluation of cell surface expression of phosphatidylserine in ovarian carcinoma effusions using the annexin-V/7-AAD assay: clinical relevance and comparison with other apoptosis parameters
Am J Clin Pathol, 132 (5), 756-62
DOI 10.1309/AJCPAVFA8J3KHPRS, PubMed 19846818

Kleinberg L, Dong HP, Holth A, Risberg B, Trope' CG, Nesland JM, Flørenes VA, Davidson B (2009)
Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma
Hum Pathol, 40 (6), 795-806
DOI 10.1016/j.humpath.2008.10.019, PubMed 19157506

Slipicevic A, Øy GF, Askildt IC, Holth A, Hellesylt E, Flørenes VA, Davidson B (2009)
Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions
Hum Pathol, 40 (4), 527-37
DOI 10.1016/j.humpath.2008.10.003, PubMed 19121847

Publications 2008

Davidson B, Dong HP, Holth A, Berner A, Risberg B (2008)
The chemokine receptor CXCR4 is more frequently expressed in breast compared to other metastatic adenocarcinomas in effusions
Breast J, 14 (5), 476-82
DOI 10.1111/j.1524-4741.2008.00625.x, PubMed 18657145

Kleinberg L, Holth A, Trope CG, Reich R, Davidson B (2008)
Claudin upregulation in ovarian carcinoma effusions is associated with poor survival
Hum Pathol, 39 (5), 747-57
DOI 10.1016/j.humpath.2007.10.002, PubMed 18439941

Publications 2007

Davidson B, Dong HP, Holth A, Berner A, Risberg B (2007)
Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells
Am J Clin Pathol, 127 (5), 752-9
DOI 10.1309/LN2075V7C8K31CH8, PubMed 17439834

Davidson B, Dong HP, Holth A, Berner A, Risberg B (2007)
Flow cytometric immunophenotyping of cancer cells in effusion specimens: diagnostic and research applications
Diagn Cytopathol, 35 (9), 568-78
DOI 10.1002/dc.20707, PubMed 17703449

Dong HP, Holth A, Berner A, Davidson B, Risberg B (2007)
Flow cytometric immunphenotyping of epithelial cancer cells in effusions--technical considerations and pitfalls
Cytometry B Clin Cytom, 72 (5), 332-43
DOI 10.1002/cyto.b.20172, PubMed 17226863

Kleinberg L, Holth A, Fridman E, Schwartz I, Shih IeM, Davidson B (2007)
The diagnostic role of claudins in serous effusions
Am J Clin Pathol, 127 (6), 928-37
DOI 10.1309/V025QRN3R9CJGNPX, PubMed 17509990

Publications 2006

Dong HP, Elstrand MB, Holth A, Silins I, Berner A, Trope CG, Davidson B, Risberg B (2006)
NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma
Am J Clin Pathol, 125 (3), 451-8
DOI 10.1309/15B66DQMFYYM78CJ, PubMed 16613351